| Literature DB >> 26869680 |
Joachim Schmitt1, Nathalie Lindner2, Monika Reuss-Borst1, Hans-Christer Holmberg3, Billy Sperlich4.
Abstract
To compare the effects of a 3-week multimodal rehabilitation involving supervised high-intensity interval training (HIIT) on female breast cancer survivors with respect to key variables of aerobic fitness, body composition, energy expenditure, cancer-related fatigue, and quality of life to those of a standard multimodal rehabilitation program. A randomized controlled trial design was administered. Twenty-eight women, who had been treated for cancer were randomly assigned to either a group performing exercise of low-to-moderate intensity (LMIE; n = 14) or a group performing high-intensity interval training (HIIT; n = 14) as part of a 3-week multimodal rehabilitation program. No adverse events related to the exercise were reported. Work economy improved following both HIIT and LMIE, with improved peak oxygen uptake following LMIE. HIIT reduced mean total body fat mass with no change in body mass, muscle or fat-free mass (best P < 0.06). LMIE increased muscle and total fat-free body mass. Total energy expenditure (P = 0.45) did not change between the groups, whereas both improved quality of life to a similar high extent and lessened cancer-related fatigue. This randomized controlled study demonstrates that HIIT can be performed by female cancer survivors without adverse health effects. Here, HIIT and LMIE both improved work economy, quality of life and cancer-related fatigue, body composition or energy expenditure. Since the outcomes were similar, but HIIT takes less time, this may be a time-efficient strategy for improving certain aspects of the health of female cancer survivors.Entities:
Keywords: Cancer survivors; cardiorespiratory fitness; energy expenditure; exercise; rehabilitation; sense wear
Mesh:
Year: 2016 PMID: 26869680 PMCID: PMC4758922 DOI: 10.14814/phy2.12693
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
The inclusion and exclusion criteria of this study
| Inclusion criteria | Exclusion criteria |
|---|---|
|
Diagnoses of cancer (ICD‐10 C00–D48) Female Completion of chemotherapy or radiation Body mass index 17–35 |
Age <18 years, >70 years Bone metastases symptomatic cardiac disease contraindication to maximal exercise testing and/or exercise training |
The anthropometric and medical characteristics (number or mean ± SD) as well as the energy expenditure at different intensities of the participants
| Group | ||
|---|---|---|
| HIIT ( | LMIE ( | |
| Age in years | 53 ± 8 | 54 ± 9 |
| Body mass index [kg/m2] | 27.0 ± 5.3 | 26.2 ± 4.3 |
| Months after initial diagnosis | 14 ± 20 | 25 ± 70 |
| Recurrent tumor | 1 (8%) | 2 (15%) |
| Type of tumor | ||
| Breast | 11 (85%) | 10 (77%) |
| Ovarian | 1 (8%) | 0 |
| Colon | 0 | 1 (8%) |
| Vaginal | 0 | 1 (8%) |
| Non‐invasive urothelial carcinoma | 1 (8%) | 0 |
| Non‐Hodgkin′s lymphoma | 0 | 1 (8%) |
| Metastases | 2 (15%) | 1 (8%) |
| Treatment | ||
| Surgical | 13 (100%) | 13 (100%) |
| Chemotherapy | 7 (54%) | 9 (69%) |
| Months since chemotherapy | 15 ± 8 | 11 ± 37 |
| Radiation | 9 (69%) | 9 (69%) |
| Months since last radiation | 13 ± 8 | 5 ± 14 |
| Antihormonal therapy | 9 (69%) | 7 (54%) |
| Still undergoing | ||
| Antihormonal therapy | 7 (54%) | 5 (39%) |
| Activity and energy expenditure during intervention | ||
| Step counts | 12.520 ± 2.746 | 12.400 ± 2.630 |
| Total energy expenditure [kcal] | 2.362 ± 294 | 2.282 ± 237 |
| Energy expenditure >3 MET [kcal] | 470 ± 205 | 413 ± 168 |
| Duration of activity >3 MET [min] | 108 ± 49 | 98 ± 40 |
| Duration of activity 0–3 MET min] | 223 ± 110 | 225 ± 71 |
| Duration of activity 3–6 MET [min] | 106 ± 46 | 97 ± 39 |
| Duration of activity 6–9 MET [min] | 2 ± 4 | 1 ± 1 |
| Duration of activity >9 MET [min] | 1 ± 2 | 0 ± 0 |
All mean (±SD) data and statistical analysis of the participants
| High‐intensity interval group ( | Low‐to‐moderate intensity group ( |
|
| ||||
|---|---|---|---|---|---|---|---|
| pre | post | pre | post | HIIT | LMIE | ||
| Peak oxygen uptake [mL/kg/min] | 27.1 ± 7.9 | 27.0 ± 7.3 | 23.8 ± 5.0 | 26.3 ± 5.6 | 0.42 (−0.02) | <0.00*(0.46) | 0.01*(1.27) |
| Oxygen uptake at 2.7 km/h [mL kg/min] | 14.6 ± 3.7 | 13.1 ± 2.6 | 13.6 ± 1.9 | 13.0 ± 1.8 | 0.02*(−0.23) | 0.18 (−0.16) | 0.34 (−0.38) |
| Body mass [kg] | 73.5 ± 14.3 | 73.1 ± 14.2 | 70.8 ± 13.6 | 70.8 ± 13.6 | 0.06 (−0.03) | 0.48 (0.00) | 0.22 (−0.18) |
| Fat mass [kg] | 27.4 ± 11.1 | 26.9 ± 10.5 | 26.9 ± 10.0 | 25.5 ± 11.6 | 0.02*(−0.05) | 0.06 (−0.13) | 0.31 (0.15) |
| Muscle mass [kg] | 44.1 ± 4.9 | 44.1 ± 5.1 | 41.7 ± 4.9 | 42.2 ± 4.8 | 0.40 (0.01) | 0.04*(0.10) | 0.24 (−0.17) |
| Fat‐free mass [kg] | 46.1 ± 5.1 | 46.2 ± 5.3 | 43.9 ± 5.0 | 44.4 ± 5.0 | 0.38 (0.01) | 0.03*(0.10) | 0.24 (−0.17) |
| General fatigue [a.u.] | 11.6 ± 2.9 | 10.3 ± 2.9 | 14.5 ± 3.6 | 11.3 ± 3.5 | 0.02*(−0.45) | <0.00*(−0.90) | 0.04*(0.30) |
| Physical fatigue [a.u.] | 10.8 ± 3.5 | 9.2 ± 2.8 | 14.1 ± 3.1 | 12.5 ± 4.5 | 0.01*(−0.52) | 0.06 (0.44) | 0.95 (0.01) |
| Mental fatigue [a.u.] | 12.2 ± 4.6 | 10.1 ± 4.0 | 12.7 ± 3.9 | 11.4 ± 3.2 | 0.01*(−0.46) | 0.07 (−0.37) | 0.50 (−0.09 |
| Reduced activity [a.u.] | 10.3 ± 3.3 | 8.6 ± 2.6 | 12.1 ± 2.6 | 10.2 ± 2.2 | 0.01*(−0.55) | 0.01*(−0.80) | 0.80 (0.04) |
| Reduced motivation [a.u.] | 12.0 ± 2.8 | 9.4 ± 3.2 | 11.2 ± 2.1 | 9.5 ± 2.6 | <0.00*(−0.85) | 0.01*(‐0.72) | 0.34 (−0.13) |
| Quality of life [a.u.] | 63.5 ± 14.1 | 73.0 ± 11.2 | 40.9 ± 11.0 | 58.3 ± 18.6 | <0.00*(0.79) | <0.00*(1.14) | 0.09 (−0.24) |
| Physical functioning [a.u.] | 83.1 ± 12.5 | 87.2 ± 11.0 | 68.8 ± 16.9 | 81.5 ± 11.3 | 0.04*(0.35) | <0.00*(0.89) | 0.07 (−0.28) |
| Social functioning [a.u.] | 69.1 ± 27.0 | 66.7 ± 28.9 | 49.9 ± 28.1 | 67.5 ± 28.4 | 0.33 (−0.08) | 0.01*(0.64) | 0.02*(−0.34) |
| Emotional functioning [a.u.] | 60.9 ± 26.0 | 71.9 ± 18.7 | 39.7 ± 24.6 | 71.2 ± 25.9 | 0.03*(0.46) | <0.00*(1.25) | 0.03*(−0.32) |
| Cognitive functioning [a.u.] | 60.3 ± 25.8 | 69.2 ± 29.5 | 60.3 ± 28.4 | 73.1 ± 24.0 | 0.07 (0.31) | 0.04*(0.48) | 0.66 (−0.06) |
| Role functioning [a.u.] | 65.5 ± 25.8 | 88.5 ± 17.1 | 41.0 ± 28.0 | 71.9 ± 22.0 | 0.01*(1.04) | <0.00*(1.23) | 0.45 (−0.10) |
| Fatigue [a.u.] | 39.2 ± 20.3 | 27.1 ± 13.9 | 68.5 ± 19.7 | 38.3 ± 21.7 | 0.02*(−0.67) | <0.00*(−1.46) | 0.02*(0.35) |
| Nausea [a.u.] | 5.1 ± 12.4 | 0.00 ± 0.00 | 12.9 ± 18.2 | 5.1 ± 14.3 | 0.09 8 (−0.53) | 0.10 (−0.47) | 0.58 (0.08) |
| Pain [a.u.] | 20.5 ± 23.7 | 19.2 ± 20.2 | 55.1 ± 30.6 | 32.0 ± 18.6 | 0.42 (−0.07) | <0.00*(−0.91) | 0.02*(0.34) |
| Dyspnea [a.u.] | 25.7 ± 31.0 | 20.3 ± 16.7 | 53.9 ± 37.4 | 33.2 ± 23.7 | 0.21 (−0.22) | 0.03*(−0.66) | 0.20 (0.18) |
| Insomnia [a.u.] | 48.8 ± 29.4 | 38.5 ± 26.9 | 61.5 ± 26.9 | 43.5 ± 25.2 | 0.02*(−0.35) | 0.01*(−0.69) | 0.32 (0.14) |
| Loss of appetite [a.u.] | 7.7 ± 20.0 | 2.5 ± 9.2 | 20.5 ± 25.6 | 7.6 ± 14.5 | 0.20 (−0.32) | 0.04*(−0.62) | 0.43 (0.11) |
| Constipation [a.u.] | 7.6 ± 14.5 | 7.7 ± 20.0 | 12.7 ± 16.7 | 7.7 ± 20.0 | 0.35 (0.00) | 0.36 (−0.27) | 0.50 (0.10) |
| Diarrhea [a.u.] | 5.1 ± 12.4 | 5.1 ± 12.4 | 33.3 ± 33.4 | 15.3 ± 29.2 | 0.50 (0.00) | 0.05 (−0.57) | 0.16 (0.20) |
| Financial concerns [a.u.] | 28.2 ± 42.7 | 25.6 ± 33.8 | 38.5 ± 35.7 | 40.5 ± 38.1 | 0.42 (−0.06) | 0.41 (0.05) | 0.69 (−0.06) |
*Significant for P < 0.05.